ARTICLE | Company News
Avant, 3M deal
June 16, 2008 7:00 AM UTC
Avant’s Celldex Therapeutics Inc. subsidiary received a non-exclusive license to 3M’s toll-like receptor (TLR) immune response modifier compounds for use as vaccine adjuvants in clinical research. Th...